research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.
Search
for
Sort by
Research
60-90 / 1000+ resultsresearch The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19
Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.
research New and Emerging Therapies for Alopecia Areata
Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
research The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs
We need safe, affordable drugs to fight coronaviruses effectively.
research Drug repositioning approach to target viral and host cells in terms of COVID-19 treatment: A review of in vivo experiments and clinical studies
Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
research The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis
Canakinumab's effect on COVID-19 outcomes is unclear.
research 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient
Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
research 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
ITK inhibitors may effectively treat alopecia areata.
research Interferon in the treatment of cutaneous T-cell lymphoma
Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
research SIDE EFFECTS OF CYCLOSPORINE COMPARED TO TACROLIMUS AMONG YEMENI KIDNEY TRANSPLANT PATIENTS WHO SHARE THE SAME ADJUVANT AGENTS: MYCOPHENOLATE MOFETIL AND PREDNISONE
Tacrolimus is a better option than cyclosporine due to fewer side effects.
research Cytokines
Cytokines are important for immune responses and treating diseases, but they can cause side effects like fever and skin issues.
research Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
Chemotherapy and cytokine therapy can cause various skin reactions, including hair loss and hypersensitivity.
research 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
research Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy
Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research Clinical Application of Development of Nonantibiotic Macrolides That Correct Inflammation-Driven Immune Dysfunction in Inflammatory Skin Diseases
Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research Why we should treat COVID-19 Long-Hauler Syndromes with Convalescent Plasma; Contained Suppressive Exosomes are likely COVID antigen-specific
Convalescent Plasma Therapy may help treat COVID-19 Long-Hauler symptoms.
research IMMUNOTHERAPY OF CANCER: IMMUNE CHECKPOINT BLOCKERS, VACCINES AND ADOPTIVE T CELL THERAPIES
Enhancing immune response can improve cancer treatment effectiveness.
research Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices
Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
research Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection
Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Immunosuppressive therapy in autoimmune disease — A review
Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.
research Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
research Sequential Immunotherapy with Tofacitinib and Low-Dose IL-2 Induces Sustained Remission in Alopecia Areata: A Proof-of-concept monocentric study
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.